{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:01:50Z","timestamp":1792180910806,"version":"4.4.0"},"reference-count":10,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>This case report highlights the therapeutic efficacy of semaglutide in a 49-year-old male with concurrent type 2 diabetes mellitus (T2DM), psoriasis (PASI 22), and metabolic dysfunction-associated steatotic liver disease (MASLD). The patient presented with metabolic dysregulation, severe psoriatic lesions, and hepatic steatosis. Initial therapies, including acitretin and topical agents, failed to yield clinical improvement. Semaglutide was initiated at 0.25\u202fmg\/week, titrated to 1\u202fmg\/week over 12\u202fweeks, alongside metformin dose adjustment. At 24\u202fweeks, the patient exhibited significant improvements: HbA1c decreased from 9.8 to 7.2%, body weight reduced by 6\u202fkg, liver enzymes returned to normal ranges, and PASI declined to 6.2. Treatment was well-tolerated with no severe adverse events.<\/jats:p>","DOI":"10.3389\/fmed.2025.1684204","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T04:15:02Z","timestamp":1757650502000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Semaglutide in the treatment of a patient with type 2 diabetes mellitus, psoriasis, and metabolic dysfunction-associated steatotic liver disease: a case report"],"prefix":"10.3389","volume":"12","author":[{"given":"Bingting","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuxiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1136\/gutjnl-2023-330110","article-title":"Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis","volume":"72","author":"En Li Cho","year":"2023","journal-title":"Gut"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40257-024-00857-0","article-title":"Managing the patient with psoriasis and metabolic comorbidities","volume":"25","author":"Bellinato","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-weekly Semaglutide in adolescents with obesity","volume":"387","author":"Weghuber","year":"2022","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1080\/09546634.2020.1826392","article-title":"Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial","volume":"33","author":"Lin","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jaad.2024.11.039","article-title":"Semaglutide use for decreasing hidradenitis suppurativa resource utilization: a retrospective cohort study utilizing TriNetX","volume":"92","author":"Hill","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2337\/dci24-0094","article-title":"Metabolic dysfunction-associated Steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American Diabetes Association","volume":"48","author":"Cusi","year":"2025","journal-title":"Diabetes Care"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.3389\/fimmu.2019.01807","article-title":"Psoriasis: obesity and fatty acids","volume":"10","author":"Manfred","year":"2019","journal-title":"Front Immunol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1080\/09546634.2019.1708853","article-title":"Liraglutide improved inflammation via mediating IL-23\/Th-17 pathway in obese diabetic mice with psoriasiform skin","volume":"32","author":"Chen","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/biom15010046","article-title":"Effects of Semaglutide treatment on psoriatic lesions in obese patients with type 2 diabetes mellitus: an open-label, randomized clinical trial","volume":"15","author":"Petkovi\u0107-Dabi\u0107","year":"2025","journal-title":"Biomolecules"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1684204\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T04:15:02Z","timestamp":1757650502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1684204\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":10,"alternative-id":["10.3389\/fmed.2025.1684204"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1684204","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"article-number":"1684204"}}